Ovarian cancer is the most fatal type of gynecological cancer. The main reason for high mortality is the development of drug resistance. It can be related to increased expression of drug transporters and increased expression of extracellular matrix (ECM) proteins. miRNA is a short noncoding RNA that regulates expression of about 60% of genes in the human genome and plays a crucial role in developing cancer, including resistance to chemotherapy.
INTRODUCTION
Ovarian cancer poses a growing threat to women's life and health and occupies the first place in mortality among gynaecological cancers [1] . Most cases of ovarian cancer are diagnosed at a very advanced stage (III or IV according to FIGO) [2, 3] . Despite the dynamic development of gynaecologic oncology, the main method of ovarian cancer treatment is the surgical treatment followed by chemotherapy [4] . The first line treatment is based on combination platinum derivatives (carboplatin or cisplatin) and taxanes (paclitaxel -PAC) [2] . The basis for choosing the second line chemotherapy regimen is sensitivity to treatment with platinum derivatives, which determines the prognosis [2] . Low chemotherapy effectiveness result from primary or developed during treatment drug resistance [5] . In over 80% of patients, it comes to recurrence cancer [2] . There are two main types of mechanism of drug resistance: cellular specific and tissue specific [6] . A cellular mechanism is based on cytostatics active removal from cancer cells. Proteins from ABC family contribute to this phenomenon [7] . Cellular mechanisms also include: repairing damaged DNA, developing point mutations in the genes that encode proteins that bind cytostatic drugs and increasing the activity of anti-apoptotic or pro-survival pathways as well as disrupting apoptotic signalling pathways [4] . On the other hand, the tissue specific mechanisms are associated with: tumour vascularization, cell density in the tumour and expression of extracellular matrix proteins (ECM) [8] . All of them changes drug distribution in tumour tissue decreasing their availability to tumour cells. Additionally, ECM proteins can induce cell adhesion mediated drug resistance (CAM-DR) leading to increased resistance to apoptosis [9] . Although many genes associated with the development of resistance to chemotherapy are known, the mechanisms of their regulation are still poorly understood. One of the ways to regulate gene expression is regulation at mRNA level by small noncoding RNA particlesdesignated as a micro RNA (miRNA). Short non-coding RNAs were discovered and described for the first time in 1993 by Victor Ambros from Harvard University [10] . miRNAs are short (19-29 nucleotides) , single-stranded non-coding RNA molecules, having a phosphate residue (5 'end) and a hydroxyl group (3' end) [11] . They play an important regulatory role in the expression of genes in both animals and plants [11] . In the case of miRNA, the regulation of gene expression takes place at the post-transcriptional level and involves interaction with mRNA [12] . The seed sequence (6-8 nucleotides) located in the 5' region of the miRNA plays a key role in this process. miRNA seed recognizes the sequence of the target mRNA complementary within the 3'UTR (untranslated region). Depending on the degree of complementarity of the mRNA to the mature miRNA, either the transcript degradation (complete or almost complete complementarity) occurs or the translation is inhibited (incomplete complementarity) [11] . Effect of miRNA expression can be pleiotropic. Modulation of one miRNA expression can affect many different genes responsible for the various mechanisms of cancer [13] . The sequences encoding miRNAs in the human genome can be located both in introns of genes and in non-endogenous areas. Some of the miRNA encoding genes may also be located within exons of other genes. miRNAs are classified in groups called of miRNA families and most of them is transcribed by RNA polymerase II [14] . Family members are characterized by: common origin, evolutionary conservation in sequence, similar mature miRNA/miRNA* (shared functional characteristics or biological function) and conserved mature miRNA-seed-target relationships [15, 16] . Very interesting is that miRNA genes in the same miRNA family are non-randomly localized around genes connected with cancer, infectious, immune system, sensory system, neurodegenerative diseases, and development [15] . A set of two or more [17] miRNAs which is transcribed from physically adjacent miRNA genes is called a cluster of miRNA. miRNAs that create the same cluster are transcribed in the same orientation without separation by any transcription unit. Clusters of miRNAs take part in controlling various important cellular processes such as tumour formation, development of lungs, heart and immune system [17] . Changes in miRNA expression have been reported in many diseases including different cancers. A miRNA profiling study showed that the pattern of miRNA expression in cancer tissues compared to normal tissues was very different [18] . miRNA can perform suppressor or oncogenic functions in cancers. As a tumour suppressor, it may inhibit cancers' growth by negative oncogenes' regulationgenerally, suppressor miRNA expression is decreased in cancer cell [19] . On the contrary, the oncogene miRNAs expression (called "oncomirs") is increased in tumours. Oncomirs promote tumours development and progression by the mechanism of down-regulating a tumour suppressors or other genes involved in for example cell proliferation or cell differentiation in cancer [19] . In ovarian cancer expression of different suppressors: miR-26b [20] , miR-29b [21] , miR-30a-5p [22] , miR-93-5p [23] , miR-106b-5p [24] , miR-125b [25] ; and oncogenes: miR-183 [26] , miR-376a [27] , miR-383-5p [28] , miR-551b-3p [29] , miR-572 [30] was described. Ovarian cancer tissue studies revealed the negative correlation between members of the miR-23 family. High expression level of miR-23a and low expression level of miR-23b were connected with the stage and degree of cancer, the differentiation level and lymph nodes metastases [31] . Much attention is currently being paid to miRNA in the context of drug resistance in ovarian cancer [12, 18, 19] . Changes in miRNA expression are associated with the development of resistance to chemotherapy in patients [32] as well as in vitro in the sensitive-resistant cell line model [32] . In PAC-resistant patients, downregulation of miR-663 and miR-622 were correlated with better prognosis [32] . Overexpression of miR-647 in the PAC-sensitive patients was correlated with good prognosis and that suggested suppressor function of miR-647 [32] . Changes in miRNA expression were also observed in cell line study. Downregulation of miR-31 expression correlated with taxane resistance in ovarian cancer cell lines [33] . In contrast upregulation of miR-98-5p was observed in cisplatin (CIS) -resistant cell lines [34] . Changes in miRNAs expression were also noted in another cancers. miR-195 expression was downregulated in temozolomid-resistant glioma cells [35] and miR-203 was downregulated in prostate cancer cells resistant to doxorubicin (DOX) [36] . The use of miRNA microarrays to analyse changes in miRNA gene expression is an effective molecular tool for the discovering new miRNA genes involved in drug resistance processes. The present study shows alterations in the miRNA expression levels in the CIS (W1CR), PAC (W1PR1 and W1PR2), DOX (W1DR), and topotecan (TOP) (W1TR) -resistant variants of W1 sensitive ovarian cancer cell line. We also identified a set of target genes that can be responsible for drug resistance in these cell lines.
MATERIALS AND METHODS

Reagents
Cisplatin, Doxorubicyn, Topotekan and Paclitaxel were obtained from Sigma (St. Louis, MO, USA). RPMI-1640 medium, fetal bovine serum, penicillin, streptomycin, amphotericin B (25 µg/ml) and L-glutamine were also purchased from Sigma. QIazol Lysys Reagent, miRNeasy Mini Kit and RNeasy MinElute Cleanup Kit were obtained from Qiagen (Hilden, Germany). GeneChip™ miRNA 3.1 Array Strip, FlashTag™ Biotin HSR RNA Labeling Kits, GeneAtlas™ Hybridization, Wash, and Stain Kit for miRNA Arrays were obtained from Affymetrix (Santa Clara, CA, USA).
Cell lines and cell culture
The human primary ovarian cancer cell line W1 was established from tumour tissue of untreated 54-year old Caucasian female patient diagnosed for serous ovarian adenocarcinoma (G3, FIGO IIIc). Cells grow as a monolayer, present epithelial morphology and adherent growth model. Sublines resistant to cisplatin (W1CR), doxorubicin (W1DR), topotecan (W1TR) and paclitaxel (W1PR1 and W1PR2) were obtained by exposure of the W1 cell line to stepwise increasing drug concentrations. Final concentration of each drug was twofold greater than the concentration in the plasma 2 hours after intravenous administration. The cells were 8-, 10-, 20-, 641-and 967-folds resistant to their selective drugs, respectively, as determined by Cell Proliferation Kit I (MTT) [37] . All cell lines were maintained as monolayer in complete medium [RPMI-1640 medium supplemented with 10% (v/v) fetal bovine serum, 2 pMlglutamine, penicillin (100 U/ml), streptomycin (100 U/ml) and amphotericin B (25 µg/ml)] at 37˚C in a 5% CO2 atmosphere.
miRNA isolation
miRNA was isolated using a reagents kit from Qiagen according to the manufacturer's protocol. The RNA was quantified using spectrophotometry by measuring the absorbance values at 260 nm and 280 nm, and the 260/280 nm ratio was used to estimate the level of protein contamination. The 260/280 nm ratios of the samples ranged from 1.8 to 2.0.
Microarray preparation, hybridization and scanning
MiRNA expression profiling was performed using microarray approach with Applied BiosystemsTM miRNA 3.1 Array Strip (ThermoFisher Scientific, Waltham, MA, USA). Detailed technical procedure was described earlier [38, 39] . Each microarray was designed in accordance with the miRBase Release 17 database, including complementary probes for: 1733 human mature miRNA, 2216 human snoRNA, CDBox RNA, H/ACA Box RNA, and scaRNA, 1658 human pre-miRNA. The full procedure for preparing miRNA for hybridization was performed using the FlashTagTM Biotin HSR RNA Labeling Kit (ThermoFisher Scientific, Waltham, MA, USA). 150 ng of previously isolated miRNA was subjected to the poly(A) tailing and biotin ligation procedure, according to the manufacturer's protocol. Biotinlabeled miRNA were hybridized to Applied BiosystemsTM miRNA 3.1 Array Strip (20 h, 48 •C). Afterwards the microarrays were rinsed and stained according to the technical protocol using the Affymetrix GeneAtlas Fluidics Station (Affymetrix, Santa Clara, CA, USA). The array strips were scanned using an Imaging Station of GeneAtlas System (Thermo Fisher Scientific, MA, USA).
Microarray analysis and gene screening
The initial analysis of the scanned array strips was performed with Affymetrix GeneAtlas Operating Software (Affymetrix, Santa Clara, CA, USA). The quality of the gene expression data was verified using quality control criteria set by the software. The obtained CEL files from the scanned microarrays were imported for further data analysis using BioConductor libraries from the "R" statistical programming language. The Robust Multiarray Average (RMA) normalization algorithm (implemented in the Affy library) was used to normalize, correct the background and calculate the expression values of all the tested miRNAs [40] . The biological annotation was obtained from the pd.mirna 3.1 library, where annotated data frame object was merged with normalized data set, leading to a complete miRNA data table. Differential expression and statistical evaluation were determined using a linear model for microarray data implemented in the "limma" library [41] . The selection criteria for significantly changed gene expression were based on the difference between folds greater than absolute 5 and p-value after false discovery rate (FDR) correction <0.05. The result of such selection was presented as scatter plots diagram showing the total number of miRNAs, up and down regulated ( Fig. 1 ). Differentially expressed miRNA were also visualized as heat map and tables. Raw data files were deposited in the Gene Expression Omnibus (GEO) repository at the National Center for Biotechnology Information (http://www.ncbi.nlm.nih.gov/geo/) under the GEO accession number GEO: GSE134061.
miRNA-Target Gene Prediction
SpidermiR package was applied to identify potential target genes for differently expressed miRNA. Differentially expressed miRNAs were used as a query for searching target genes in the following databases: for predicted targets-DIANA, Miranda, PicTar, TargetScan, and for experimentally validated targets-miRTAR, miRwalk [42] . To determine the actual expression value of target genes, mRNA transcriptomic data from our published experiment were used [43] [44] [45] . Obtained fold change values for mRNA were assigned to target genes data table. For further analysis, we have selected only those target genes for which fold change was inversely correlated with the fold change value of appropriate miRNA (cut-off criteria: fold ± 5, adjusted p-value (adj.p.val.) < 0.05). From the whole set of miRNA-targets pairs, we selcect only those that were involved in drug resistance, extracellular matrix and cancer stem cell biology using a following key words in GO terms: "collagen-containing extracellular matrix", "extracellular matrix", "extracellular space", "response to drug" and "stem cell". Interactions between miRNA and target genes, in the form selected GO terms, were visualized using Cytoscape 3.7.1 [46] .
Fig. 1.
Scater plots displaying the miRNA with expression levels that were up-regulated (green dots) or down-regulated (red dots) by fivefold and more in drug resistant cells in relation to the insensitive W1 cells. Grey dots indicated genes bellow cut-off criteria.
RESULTS
Gene chip quality assessment
In the present study, we used standard factors such as signal to noise ratio internal hybridization, controls spike-in-controls to preliminarily determine the quality of analysed samples. Controls sipke-in-controls: spike_in-control-2, spike_in-control-23, spike_in-control-29, spike_incontrol-31, spike_in-control-36. Oligos 2, 23 and 29 are RNA, confirm the poly(A) tailing and ligation. Oligo 31 -poly(A) RNA -confirms ligation. Oligo 36 is poly(day) DNA and confirms ligation and the lack of RNases in the RNA sample.
Gene expression evaluation and gene expression lists
We evaluated changes in transcription level of miRNA genes. Analysis of the gene expression in five drug resistant ovarian cancer cell lines provided a new information about the significance of changes in miRNA genes expression in drug resistance development in ovarian cancer. Table  I summarise the changes in the expression of miRNA genes in drug resistant sublines with respect to drug sensitive W1 cell line. Statistically significant level changed in the drug-resistant cells relative to that in their drug-sensitive counterparts by higher than 5-fold, and less than 0.2fold (up-/down-regulation of more than/less than 5 and -5, respectively) was evaluated. Genes with expression levels of between 5-and 0.2-fold those of the controls were considered 'not significant (NS)' when the gene lists were constructed.
miRNA gene expression in drug resistant cell lines
We observed alterations in the expression of 40 miRNA genes (Table I, Fig. 2 ). The level of expression of 21 genes was upregulated in at least one drug resistant cell line. Expression of 19 genes were downregulated in at least one drug resistant cell line.
In relation to the determined cut-off criteria (fold +-5, p<0.05), the most alternations were observed for W1PR1 (PAC resistant cell line) -25 miRNA with altered expression (14 genes upregulated and 11 genes downregulated). Changes in expression of 12 miRNA were observed for W1PR2 cell line with 5 genes upregulated and 7 genes downregulated. Much less changes were observed for other drug resistant cell lines. In CIS resistant cell line, we observed changes in 9 miRNA genes (5 genes upregulated and 4 genes downregulated). In TOP resistant cell line changes in 8 genes expression were observed (3 genes upregulated and 5 genes downregulated) and finally in DOX-resistant cell line we observed changes in expression of 7 genes (1 gene upregulated and 6 genes downregulated).
Based on the following standards, we selected 27 of 40 miRNA genes for further analysis. 1) miRNA genes with changes in expression at least 5-fold (up or down) in at least three drug resistant cell lines; 2) at least 10-fold changes in miRNA gene expression in one drug resistant cell line; 3) 5-fold changes in expression of at least two miRNA genes from the same family.
Expression of miR-31 and miR-449c changed in four drug resistant cell lines (W1PR1, W1PR2, W1CR and W1TR). Expression of miR-105, miR-1271, miR-152, miR-767-5p and miR-875-3p changed in three drug resistant cell lines. Expression of 12 miRNAs was changed at least 10-fold in one tested line, and between them expression of miR-10a, miR-146b-5p, miR-18b, miR-214, miR-29a, miR-363 was downregulated and expression of miR-145, miR-195, miR-203, miR-30a, miR-335 and miR-99a was upregulated.
Expression of miRNA from families 181 (miRNA-181a and miRNA-181b), 193 (miRNA-193a-5p and miRNA-193b), 199 (miRNA-199a-3p and miRNA-199b-3p) and 23 (miRNA-23b and miRNA-23c has also been changed in investigated cell lines. What is important the expression of miRNAs belonging to the same family has been altered in the same way. Especially members of 193 and 23 families were upregulated in W1PR1 cell line and members of 181 and 199 family were downregulated in W1TR and W1DR cell lines, respectively.
High similarity between cell lines resistant to PAC was observed. In both cell lines the same six genes (miR-105, miR-10a, miR-31, miR-449c, miR-767-5p and miR-875-3p) were downregulated and miR-152 was upregulated. Some similarity was also observed between both PAC and CIS resistant cell linedrug used in the first line chemotherapy of ovarian cancer.
Of the 27 genes selected for analysis, nine showed a very significant level of expression change, >20 fold. miR-31 was downregulated in four cell lines (W1PR1, W1PR2, W1CR and W1TR) with very strong downregulation more than 217-fold in W1PR1 cell line and strong downregulation -52-fold in W1PR2 cell line and 36-fold in W1TR cell line. Among other significantly downregulated genes, we observed downregulation of miRNA-10a (34-fold), miRNA-146b-5p (39-fold) and miRNA-767-5p (20-fold) in W1PR1 cell line. We also observed a significant downregulation of miR-105 in W1PR2 (22- 
Analysis of target genes expression
In the second part of our investigation we were interested if described miRNAs are involved in regulation of genes responsible for drug resistance development. By the assumption that increasing miRNA expression leads to decreasing target gene expression and vice versa, for further analysis we selected those target genes in which the fold change was inversely correlated with the fold change of miRNA and changes at least five times up/down respectively with adj. p val<0.05. Targets with expression levels of between 5-and 0.2-fold (up/down regulation between 5 and -5) those of the controls were considered 'not significant (NS)' when the target gene lists were constructed. For analysis of target genes expression we used our microarray data that were published previously [43] [44] [45] . From target genes analysis we excluded miRNAs expressed only in W1PR2 cell line, because we do not possess mRNA microarray data for this cell line. So, the following miRNAs were excluded from analysis: miR-1285, miR-30a, miR-4721, miR-501-5p, and miR-572. Using our criteria (changes in expression 5 fold up or down) we did not found any targets for the following miRNA: miR-1271, miR-152, miR-203, miR-335 and miR-214.
For further analysis we selected genes involved in drug resistance, extracellular matrix and cancer stem cell biology using a following key words in GO Data Base: response to drug, drug transport, extracellular space, extracellular matrix, collagen containing extracellular matrix, stem cell, because previously we described changes in expression of genes from these groups in investigated drug resistance cell lines (43) (44) (45) . Using this criteria we did not found targets for the following miRNA: miR-100, miR-10a, miR-143, miR-193a-5p, miR-199a-3p, miR-199b-3p, miR-4269 and miR-99a.
In CIS resistant cell line we identified targets for miR-767-5p, miR-195 and miR-708. Among them miR-195 overexpression correlated with SLC2A14 (solute carrier) transporter downregulation (Fig.3) . In DOX resistant cell line we found targets for miR-146b-5p, miR-205 and miR-875-3p, and among them we could distinguish Semaphorin 6A (SEMA6A) regulated by miR-875-3p ( Fig. 4 ).
Much more targets were identified in PAC and TOP resistant cell lines and among them important genes related to drug resistance or other features of cancer cells. In W1PR1 cell line we observed invers correlation between expression of miR-363 and key drug resistant gene ABCB1 (ATP Binding Cassette Subfamily B Member 1). Expression of important collagens -COL3A1 (Collagen Type III Alpha 1 Chain) and COL5A2 (Collagen Type V Alpha 2 Chain) was correlated with miR-767-5p, overexpression of receptor tyrosine kinases EPHA7 (Ephrin Type-A Receptor 7) was associated with downregulation of miR-18 and miR-20b. miR-20b and miR-146b-5p downregulation also was correlated with upregulation of MAP3K8 (Mitogen-Activated Protein Kinase Kinase Kinase 8) . SEM3A (Semaphorin 3A) and MYC (Myelocytomatosis Viral Oncogene Homolog) down regulation was associated with overexpression of miR-145. MYC expression was also regulated by let-7c. Upregulation of miR-497 and miR-195 was associated with PCDH9 (Protocadherin 9) downregulation ( Fig. 5 ). Changes in different miRNAs were also associated with changes in expression of important drug resistant genes in W1TR cell line. miR-181a and miR-181b downregulation was associated with increased expression of SPP1/OPN (Secreted Phosphoprotein 1/ Osteopontin), TGFBI (Transforming Growth Factor Beta Induced), LOX (Lysyl Oxidase), EPHA7, DCN (Decorin) and MAP3K8 (only miR-181b). Expression of SPP1 was also associated with miR-449c downregulation and miR-449c downregulation correlated with SEMA3D (Semaphorin 3D) overexpression. Similarily, in W1PR1 cell line MYC downregulation was associated with overexpression of miR-145. Very high upregulation of COL3A1 was associated with downregulation of miR-29a in this cell line (Fig.6 ).
Discussion
The present study demonstrates the correlation between resistance to cytotoxic drugs and expression of genes encoding micro RNA. Genes up-or down-regulated less than 5-fold were considered as not significantly altered and not taken into consideration. Between genes that are up-or down-regulated between 5-and 10-fold we consider only those that are changed in at least three drug resistant cell lines or coordinate expression of two genes from the same family is observed. All genes with expression up-or down-regulated more then 10-fold are considered as an important in drug resistance development.
It has been reported that changes in miRNA genes expression can be related to development of chemotherapy resistance in solid tumours as well as in development of resistance of cancer cell lines to cytotoxic drugs in vitro [47] . Thus, in present study we analysed changes in expression of several miRNAs in ovarian cancer cell lines resistant to drugs from the first line (CIS and PAC) as well as from second line of chemotherapy (DOX and TOP). We were especially interested in changes of miRNA genes expression in cancer cells exposed to drugs with different mechanism of action. In contrast to studies in which only one pair of sensitive/resistant cell lines is tested, in this study changes in miRNA expression in five drug resistant cell lines among which PAC-resistant twin cell lines were examined. It is a unique model for such research.
Among the 27 miRNAs analysed in this experiment, we could observe significant downregulation of miR-31 and miR-449c in four out of five drug resistant cell lines. Such a significant decrease in expression in cell lines resistant to CIS, TOP and, which is noteworthy, in both PAC resistant cell lines, may indicate a role in the process of resistance to these drugs. This is supported by other studies in which a downregulation of miRNA-31 induced taxane resistance in ovarian cancer cells. miR-31 was downregulated in a PAC resistant cell line, and reintroduction of miR-31 again sensitized them to PAC both in vitro and in vivo [33] . The miR-31 suppressor effect in ovarian cancer cell line and tissue has been confirmed by Hassan M.H. et al. [48] . They observed a high level of miR-31 in the chemosensitive serous ovarian cancer cell line and decrease in taxane-resistant line [48] . All these results suggest that downregulation of miR-31 expression may be associated with PAC resistance in ovarian cancer. The potential role of reduced miR-31 expression in CIS resistance can also be assumed. This is demonstrated by the results of our study, in which significant downregulation in CIS-resistant cell line was noted. This is in line with the results of other studies that showed decreased miR-31 levels in CIS-resistant tumours and cell line of gallbladder cancer (GBC). In contrast, the ectopic expression of miR-31 in a CIS-resistant cell line causes an increased CIS sensitivity [49] . Because in our study, for the first time, we observed downregulation of miR-31 expression in a TOP-resistant cell line, the potential contribution of miR-31 to the development of TOP resistance requires further investigation.
Unlike miR-31, expression of miR-449c has not been described in the literature in the context of drug resistance in cancer. Since we have demonstrated a downregulation of miR-449c in cell lines resistant to different cytotoxic agents, this may suggest its non-specific role in drug resistance. Previously, we observed ALDH+ stem cell like population in W1PR1, W1TR and W1PR2 cell lines [50, 51] . Here, we observed downregulation of miR-31 and miR-449c in all these cell lines, and importantly, the level of these miRNAs downregulation was inversely correlated with the number of ALDH+ cell population. This suggest the role of miR-31 and miR-449c downregulation in development of stem cell population. Lv C. et al. showed that miR-31 plays a critical role in mammary stem cell self-renewal and breast tumorigenesis by regulating Wnt pathway [52] .
Increased expression of miR-1271 in our PAC-, CIS-and TOP-resistant cell lines contradicts the results of other investigators. Expression of miR-1271 was downregulated in gastric cancer and cell lines in comparison to healthy tissues and cells and further downregulated in CISresistant cell lines [53] . Glioblastoma patients with low level of miR-1271 have shorter overall survival than patients with higher level [54] .
We have demonstrated significant downregulation of three subsequent miRNAs: miR-105, miR-767-5p in CIS and PAC-resistant and miR-875-3p in PAC and TOP-resistant cell lines. Lu G. et al. showed that in NSCLC low miR-105 expression was associated with poor patient survival, suggesting its hypothetical role in chemotherapy resistance [55] . In contrast, in triple negative breast cancer, it was shown that miR-105 was upregulated and correlated with poor patient survival and promoted chemoresistance [56] . However, clinical study does not reflect a simple drug sensitive/resistant cell line model. In contrast, we did not found any data about the role of miR-767-5p and miR-875-3p in drug resistance. Thus, the role of miR-767-5p, miR-875-3p in drug resistance can be considered possible, but drawing specific conclusions requires more thorough research.
Upregulation of two another miRNAs (miR-152 and miR-195) in cell lines resistant to CIS and PAC could indicate their involvement in the regulation of genes associated with resistance to first line chemotherapy of ovarian cancer. However, in contrast to our study downregulation of miR-152 and miR-195-5p was observed in CIS-resistant ovarian cancer cell lines [57, 58] . On the other hand, the upregulation of miR-195 has been observed in PAC-resistant laryngeal cancer cell line [59] and docetaxel resistant head and neck squamous cell carcinoma [60] . Thus, the role of this miRNAs in drug resistance could be cell and drug type dependent.
Based on the second research hypothesis assumed in advance, a group of miRNAs whose expression level was changed at least 10-fold in one drug resistant cell line was selected. In this group, as many as nine different miRNAs (miR-10a, miR-146b-5p, miR-203, miR-30a, miR-363, miR-18b, miR-145, miR-195 and miR-99a) showed changes in expression level in PAC resistant cell lines. However, we could also observe high changes in expression of single miRNAs in CIS-(miR-195, miR-203), TOP-(miR-29a, miR-145, miR-335) and DOXresistant (miR-146b-5p, miR-214) cell lines. We are aware that the obtained results cannot clearly indicate the role of these molecules in the development of drug resistance. Some of them were described here for the first time (miR-99a, miR-145 and miR-18b). For others, we searched any literature data describing their involvement in the context of drug resistance or, if not found, at least in the pathogenesis of various cancers.
As the result of literature search we found that other research teams described the changes in expression levels of the same miRNAs as ours. In contrast to our result, where decreased level of miR-10a in PAC-resistant cell line was noted, Sun W. et al. observed increased expression level in CIS-resistant A549 lung cancer cell line. Furthermore, miR-10a silencing, increases sensitivity of resistance cell line to CIS [61]. These differences can result from different drugs and different cancer type used in both study. Further studies report that low level of miR-146b-5p expression correlates with ovarian cancer progression. In advanced cancer stage (III/IV) the level of miR-146b-5p expression was lower compared to earlier stage (I, II) [62] . In cell line study overexpression of miR-146b-5p enhanced ovarian cancer cell sensitivity to PAC and CIS [62] . Thus, miR-146b-5p downregulation seems to play a role in resistance of ovarian cancer to cytotoxic drugs, especially to PAC.
In opposite to our result (upregulation in PAC and CIS resistant cell lines) Cheng R. et al. shown that in CIS-resistant NSCLC tumours miR-203 was downregulated compare with CIS-sensitive tumours [63] . Ectopic expression of miR-203 in NSCLC cell line increases CIS sensitivity and apoptosis [63] . Overexpression of miR-203 also reversed PAC-resistance in colorectal cancer [64] . Regarding the miR-30a, the increase in expression of which we observed PAC-resistant cell line, Sestito et al. miR-30a was downregulated in CIS-and PAC-resistant ovarian cancer cell lines [22] and overexpression of miR-30a caused increased sensitivity of ovarian cancer cells to CIS-induced apoptosis [22] .
In contrast to our report, Mohamed Z. et al. [65] observed upregulation of miR-363 in PAC resistance ovarian cancer cell line. Furthermore, overexpression of miR-363 confers PAC resistance and inhibition of miR-363 restores the response to PAC [65] . In contrast downregulation of miR-363 was observed in CIS-resistant hepatocellular carcinoma cell line [66] . Significantly lower expression level of miR-363 was also observed by Cao L. et al. in CIS-resistant ovarian cancer cell line [67] . Thus, the significance of miR-363 in drug resistance can be cell line dependent.
The next three miRNAs described in this report hypothetize their involvement in resistance to DOX, CIS and TOP. In ovarian cancer cell line study downregulation of miR-29a correlated with increased CIS resistance, while overexpression of miR-29a correlated with sensitized ovarian cancer cell line to CIS [68] . Similar results were obtained by Yang L. et al. in glioblastoma stem cells in which overexpression of miR-29a in CD133+ GBM (glioblastoma multiforme) stem cells effectively reversed the resistance to CIS [69] . Downregulation of miR-29a was also observed in methotrexate resistant osteosarcoma cell line [70] . Here, we observe downregulation of miR-29a in TOP-resistant cell line. Thus, it appears that a downregulation of miR-29a could be involved in cytotoxic drug resistance.
In our study miR-335 is significantly upregulated in TOP-resistant cell line. In contrast, downregulation of miR-335 was observed in PAC and CIS resistant A2780 ovarian cancer cell lines [71] . In DOX-resistant cell line we could observe very significant downregulation of miR-214. Downregulation of this miR was also observed in DOX-resistant urothelial bladder cancer tissues and cells lines [72] . Thus, the miR-214 can by a potential marker of DOX resistance. We for the first time observe upregulation of miR-99a, miR-145 and downregulation of miR-18b in PAC-resistant cell line. Upregulation of miR-99a was observed in CIS-resistant gastric cancer cell lines [73] and vincristine-resistant acute lymphoblastic leukemia (ALL) [74] . In contrast to our study, downregulation of miR-145 was observed in PAC-resistant variants of A2780 and SKOV-3 ovarian cancer cell lines [75] . We did not find any information about the significance of miR-18b in drug resistance in general. Thus, its role in drug resistance require further investigation.
It is assumed that miRNAs from the same family can play a very similar role in regulation of genes expression. Therefore, as the last step in our research, we analysed changes in miRNAs expression in the same families. In our study miR-193a-5p miR-193b are upregulated in PACresistant cell line that suggest they can regulate expression of gene involved in resistance to this drug. As demonstrated by Khordadmehr et al., the miR-193 family (miR-193a-3p, miR-193a-5p, miR-193b3p, and miR-193b-5p) plays an important role in the pathogenesis of ovarian cancer [76] . A similar result was obtained for miR-23 family members -miR-23b and miR-23c. As there is no literature data describing the contribution of these miRNAs as a cluster to cytostatic resistance, at this stage one can only assume that they may affect the expression of genes associated with PAC resistance. However, the upregulation of miR-23b correlated with better survival of lung cancer patients [77] and on the other hand with DOX-resistance in thyroid cancer cells [78] . In another study downregulation of miR-23b and miR-27b was observed in MDR Ehrlich ascites tumor cells [79] . Thus, the role of these miRs in drug resistance require further investigation. On the other hand, the downregulation of miR-181a and miR-181b in TOP-resistant ovarian cell line, might be an indicator of their involvement in development of TOP resistance. However, their role in TOP-resistance have not been investigated by others. Decreased expression of miR-181a was observed in CIS-resistant cervical cancer cell line [80] and miR-181b in NSCLC cell CIS-resistant cell line [81] .
Members of miR-199 family were described in ovarian cancer. Cheng W. et al. showed that miR-199a-3p and miR-199a-5p overexpression significantly decrease chemoresistance of cancer-initiating cells (CICs) to CIS, PAC, and DOX and reduced mRNA expression of the multidrug resistance gene ABCG2 in vivo [82] . miR-199b-5p silencing is significantly associated with acquired chemoresistance in ovarian cancer cell line and cancer tissue [83] .
Here we observed significant downregulation of miR-199a-3p and miR-199b-3p in a DOXresistant cell line. However, as previously reported, ABCG2 gene expression has not changed in this cell line [43] . In contrast, this cell line was characterized by overexpression of the MDR1 gene. Determining the involvement of miR-199 family members in the regulation of drug resistant genes require further investigation.
As presented above, both our results and studies of other researchers indicate some involvement of specific miRNAs in the process of drug resistance. However, the interpretation of miRNA expression results is much more complicated compared to gene encoding proteins.
As an example, the expression of MDR1 gene encoding P-gp protein is always related to drug resistant phenotype. In the case of miRNA genes, this phenomenon more comprehensive. On the one hand, one miRNA gene can regulate the expression of different mRNAs, and from other hand, the same mRNA can be regulated by different miRNAs. This generates a complex network of dependencies. Another aspect that affects the complexity of those relationships is related to the fact that different genes are involved in the drug resistance. From our experience in working on several drug sensitive/resistant pairs of cell lines and based on literature data, we know that some specific genes are involved in resistance to a particular cytostatics, e.g. MDR1
is very often expressed in PAC and DOX resistant cell lines, and ABCG2 gene, encoding BCRP is very often expressed in TOP-resistant cell lines [45, 84] . However, in addition to these canonical genes of drug resistance, there are many other genes whose altered expression is observed in drug resistance, among them e.g. genes encoding extracellular matrix proteins (ECM) that seems to be involved in cell adhesion mediated drug resistance (CAM-DR) [44, 85] .
Considering the high complexity of the process of acquiring resistance by cancer cells, and summarizing the results obtained in this study, we believe that the contribution of miR-31, miR-146b, miR-195 in PAC-, miR-214, miR-199a-3p and miR-199a-5p in DOX resistance is highly possible. However, the role of the described miRNA genes requires further molecular, cellular and bioinformatics analysis, which we intend to proceed in the next step of our study.
To shed a more light on the role of investigated miRs in drug resistance in the second part of our study we analysed correlation between expression of miRs and their targets. We were mainly interested if genes described by ours previously in the context of drug resistance can be regulated by miRNAs, although some other genes are also discussed.
In our previous microarray analysis [43] [44] [45] 84, 85] we could observe much more genes with changed expression in PAC-and TOP-resistant cell lines than in CIS-and DOX-resistant ones. This seems also to be reflected by number of targets to miRNAs identified in GEO database in these cell lines. Thus, according to number of identified targets we can divide our cell lines into those with low number of identified targetsrepresented by CIS-and DOX-resistant cell lines and those with high number of identified targets, represented by PAC-and TOP-resistant cell lines.
In W1CR1 cell line the only gene that was described in context of CIS-resistance was SLC2A14 regulated by miR-195 [45] . The only gene described in context of drug resistance in DOXresistant cell line was SEMA6A regulated by miR-875-3p. However, in contrast to our results downregulation of SEMA6A was observed in DOX-resistant A2780 ovarian cancer cell line [86] . Thus, the role of this miR and its target in drug resistance require further investigation.
As we described previously [37] the most important gene responsible for PAC resistance in W1PR1 cell line was ABCB1 (MDR1) encoding the glycoprotein P (P-gp). Here we observe that upregulation of this gene is related to downregulation of miR-363 in this cell line, that is the first such observation. However, downregulation of miR-363 was associated with ABCC1 overexpression in oxoplatin hepatocellular carcinoma cell lines [87] .
Previously we reported overexpression of several collagen genes in different drug resistant ovarian cancer cell lines [88] . In this experiment, we could observe that increased expression of COL3A1 and COL5A2 inversely correlates with miR-767-5p level. Thus, expression of this two genes seems to be regulated by this miRNA. Similarily, we observed downregulation of miR-767-5p in W1PR2 cell line accompanied by very strong COL3A1 upregulation [88] . This further support the possible role of miR-767-5p in COL3A1 gene regulation.
Drug resistant cells are characterized by strong signal transduction. Previously we reported increased total pTYR level in drug resistant cell lines in comparison to parental cell lines W1 [89] . Here, we observe that upregulation of receptor tyrosine kinase -EPHA7 and MAP3K8 kinase is inversely correlated with miR-18b (EPHA7) and miR-18b and miR-20b (EPHA7 and MAP3K8). Regulation of EPHA7 expression by miR-18b was also described by others [90] .
It has been reported that signal transduction by EPHA7 receptor may activate ERK signalling pathway that also involves MAP3K8 [91] . Upregulation of EPHA7 was observed in many cancers including hepatocellular carcinoma where it was associated with tumour progression, invasiveness and metastasis [92] . MAP3K8 was described as a mediator of vemurafenib resistance of thyroid cancer stem cells [93] .
SEMA3A is a member of semaphorin family of proteins that play a role in many developmental processes but also in cancer progression [94] . It is a tumour suppressor gene and its downregulation correlates with progression of gastric [95] and ovarian cancer [96] . Recently we described SEMA3A downregulation in three PAC-resistant ovarian cancer cell lines [97] .
Here we showed that expression of SEMA3A can be influenced by miR-145 upregulation in PAC resistant cell line. Regulation of SEMA3A by miR-145 is not surprising because SEMA3A as a direct target of miR-145 has been described recently [98] . The upregulation of miR-145 was also discovered as connected with strong downregulation of Myc Proto-Oncogene Protein in W1PR1 cell lines. miR-145 has been described as a suppressor miRNA that directly target MYC transcript in esophageal squamous cell carcinoma [99] and ovarian cancer [100] .
Moreover, as our analysis shows, the MYC downregulation can be due to let-7c upregulation in this cell line as well, that was described previously in prostate cancer cells [101] .
Another gene, found to be downregulated in PAC resistant cell line was PCDH9, the expression on which correlated with miR-195 and miR-497 upregulation. PCDH9 (protocadherin 9) a member of protocadherin protein family [102] is a calium-dependent adhesion protein playing role in neural cell interaction [103] . It is a tumour suppressor gene with decreased expression in ovarian [104] and gastric cancer [105] and its downregulation usually correlates with disease progression and shorter survival. Previously we observed the PCDH9 downregulation in three PAC resistant cell lines [97] suggesting its significance in resistance to this cytotoxic agent. However, there are no literature data available describing the regulation of PCDH9 gene by miR-195 or miR-497.
The very important role in TOP-resistant cell line play downregulation of miR-181a and miR-181b, since their downregulation was inversely correlated with upregulation of key genes involved in drug resistance. As in W1PR1 cell line also in W1TR cell line we observed increased total pTYR level [89] . Additionally, increased EPHA7 and MAP3K8 level was noted as well. It can be associated with stronger signal transduction, increased pTYR level and eventually drug resistance. As opposed to W1PR1 cell line both genes are regulated here by miR-181a and miR-181b, which is the first such observation described so far.
We could also observe that both -miR-181a and miR-181b -regulate DCN and LOX genes' expression. DCN (decorin) is a small leucine reach proteoglycan, a part of ECM that bind to collagens and play an important role in cancer development and metastasis [106] . Regulation of DCN by miR-181 has been reported in skin and wound healing [107] . LOX (lysyl oxidase), is a secretory protein involved in cross-linking of collagens and elastin in the ECM that results in increase ECM stabilization [108] . Its expression seems to be an important metastatic factor in breast [109] and ovarian [110] cancer among others. Previously we described increased expression of LOX in PAC and TOP resistant ovarian cancer cell lines and its expression was upregulated in ALDH1A1 positive cells [51] . However, the regulation of LOX gene by miR-181a or miR-181b was not described in literature so far.
Two other genes important in drug resistance and cancer progression were also regulated by miR from 181 family as well as miR-449c. TGFBI (transforming growth factor-beta-induced protein), is a collagen I, II and IV binding protein present in ECM. It has been described as the metastasis promoting protein in ovarian cancer [111] and its expression was correlated with shorter survival of patients with serous ovarian cancer [112] . Recently we also described TGFBI as a gene related to TOP resistance in three different ovarian cancer cell lines [43] . It has been proved that expression of TGFBI is regulated by miR-181a in osteoblast during differentiation [113] .
SPP1 (secreted phosphoprotein 1), also known as osteopontin (OPN), was originally described in bone tissue [114] , however its expression was also described in different cancers including ovarian [115] , as a protein involved in tumor progression, metastasis and drug resistance [116] . It has been reported that PAC-, DOX-and CIS-resistance was related to induction of drug transporters protein expression by SPP1 [117] or blocking caspase [118] . Recently we also described expression of SPP1 protein in three TOP resistant cell lines [43] . Similar to our results, the downregulation of miR-181a and upregulation of OPN mRNA were observed in CIS-resistant cervical cancer cells [80] and overexpression of miR-181a led to reduced expression of OPN and higher sensitivity to CIS. Regulation of OPN by miR-181b was described also in eosinophilia in astma [119] . In contrast regulation of SPP1 by miR-449c has not been described so far.
As we described previously W1TR cell line was characterized by abundant COL3A1 expression, that was secreted from the cells [88] . COL3A1 was also described as a protein involved in CIS resistance in ovarian cancer [120] . Here we observed that upregulation of COL3A1 inversely correlates with downregulation of miR-29a. In similar way upregulation of COL3A1 was observed in two MTX resistant osteosarcoma cell lines and correlated with miR-29a downregulation. Furthermore, it has been proved that miR-29a regulate COL3A1 expression [70] .
In summary, we identified a set of potential or already described targets for miRs with altered expression in drug resistant cell lines. Some of these targets have previously been described as an important factor in development of drug resistance and/or cancer progression. The way of regulation of some of these target genes by miRs described in our study was previously described. Regulation of other targets require detailed study at molecular level and significance of this regulation need to be confirmed in context of drug resistance.
